GLP1R and endothelial dysfunction: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising agents in reducing infarct size due to their antioxidant and anti-inflammatory properties, which may mitigate endothelial dysfunction, but current studies have shown mixed results, not allowing implementation in clinical practice (13–16).